ATE110380T1 - Verfahren zur verringerung der kristallgrösse von ondansetron-hydrochlorid-dihydrat. - Google Patents

Verfahren zur verringerung der kristallgrösse von ondansetron-hydrochlorid-dihydrat.

Info

Publication number
ATE110380T1
ATE110380T1 AT90307044T AT90307044T ATE110380T1 AT E110380 T1 ATE110380 T1 AT E110380T1 AT 90307044 T AT90307044 T AT 90307044T AT 90307044 T AT90307044 T AT 90307044T AT E110380 T1 ATE110380 T1 AT E110380T1
Authority
AT
Austria
Prior art keywords
reducing
hydrochloride dihydrate
ondansetron hydrochloride
crystal size
size
Prior art date
Application number
AT90307044T
Other languages
English (en)
Inventor
David Trevor Collin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10659180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE110380(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE110380T1 publication Critical patent/ATE110380T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Otolaryngology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Glass Compositions (AREA)
AT90307044T 1989-06-28 1990-06-27 Verfahren zur verringerung der kristallgrösse von ondansetron-hydrochlorid-dihydrat. ATE110380T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898914804A GB8914804D0 (en) 1989-06-28 1989-06-28 Process

Publications (1)

Publication Number Publication Date
ATE110380T1 true ATE110380T1 (de) 1994-09-15

Family

ID=10659180

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90307044T ATE110380T1 (de) 1989-06-28 1990-06-27 Verfahren zur verringerung der kristallgrösse von ondansetron-hydrochlorid-dihydrat.

Country Status (20)

Country Link
US (1) US5622720A (de)
EP (1) EP0415522B1 (de)
JP (1) JP3093242B2 (de)
KR (1) KR0182789B1 (de)
AT (1) ATE110380T1 (de)
AU (1) AU637110B2 (de)
CA (1) CA2019944C (de)
DE (1) DE69011786T2 (de)
DK (1) DK0415522T3 (de)
ES (1) ES2060045T3 (de)
GB (1) GB8914804D0 (de)
HK (1) HK44495A (de)
HU (1) HU208009B (de)
IE (1) IE64715B1 (de)
IL (1) IL94888A (de)
NZ (1) NZ234267A (de)
RU (1) RU2002745C1 (de)
SA (1) SA90110025B1 (de)
UA (1) UA18249A (de)
ZA (1) ZA905002B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
RU2185825C1 (ru) * 2001-03-12 2002-07-27 Государственный научный центр - Институт биофизики Фармацевтическая композиция, содержащая ондансетрон и метацин
MXPA04007995A (es) * 2002-02-19 2004-11-26 Teva Pharma Desolvatacion de solvatos de hemicalcio de atorvastatina.
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
MXPA04010846A (es) * 2002-04-29 2005-01-25 Biogal Gyogyszergyar Proceso para preparar 1, 2, 3, 9-tetrahidro -9- metil-3 -[(2-metil -1h-imidazol -1-il) metil]- 4h- carbazol -4- ona.
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7288660B2 (en) 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CN101123946B (zh) * 2005-02-23 2013-06-26 泰华制药工业有限公司 改良含量均匀度的雷沙吉兰制剂
EP2007369A4 (de) 2006-04-03 2009-07-01 Teva Pharma Verwendung von rasagilin zur behandlung des syndroms der ruhelosen beine
CA2666512C (en) * 2006-10-24 2014-05-27 Helsinn Healthcare S.A. Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU193592B (en) * 1984-01-25 1987-11-30 Glaxo Group Ltd Process for producing tetrahydro-carbazolone derivatives
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
JP2608078B2 (ja) * 1986-12-17 1997-05-07 グラクソ、グループ、リミテッド 医 薬
DK185489A (da) * 1988-04-22 1989-10-23 Duphar Int Res Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron

Also Published As

Publication number Publication date
HK44495A (en) 1995-03-31
HU208009B (en) 1993-07-28
IE902333A1 (en) 1991-01-16
EP0415522A1 (de) 1991-03-06
UA18249A (uk) 1997-12-25
RU2002745C1 (ru) 1993-11-15
DE69011786T2 (de) 1994-12-15
CA2019944C (en) 2000-05-09
DK0415522T3 (da) 1994-09-19
KR0182789B1 (ko) 1999-10-15
US5622720A (en) 1997-04-22
CA2019944A1 (en) 1990-12-28
EP0415522B1 (de) 1994-08-24
KR910000709A (ko) 1991-01-30
AU5787490A (en) 1991-01-03
HUT54140A (en) 1991-01-28
NZ234267A (en) 1992-11-25
AU637110B2 (en) 1993-05-20
IE902333L (en) 1990-12-28
ES2060045T3 (es) 1994-11-16
JPH0395178A (ja) 1991-04-19
HU904015D0 (en) 1990-12-28
IL94888A (en) 1995-03-15
JP3093242B2 (ja) 2000-10-03
GB8914804D0 (en) 1989-08-16
SA90110025B1 (ar) 2001-03-24
ZA905002B (en) 1991-12-24
IL94888A0 (en) 1991-04-15
DE69011786D1 (de) 1994-09-29
IE64715B1 (en) 1995-08-23

Similar Documents

Publication Publication Date Title
DE69011786D1 (de) Verfahren zur Verringerung der Kristallgrösse von Ondansetron-hydrochlorid-dihydrat.
DE69233314D1 (de) Verfahren zur Herstellung von Halbleiter-Produkten
DE69112463D1 (de) Vorrichtung zur Herstellung von Monokristallen nach dem Czochralski-Verfahren.
DE3750076D1 (de) Verfahren zur Veränderung der Eigenschften von Halbleitern.
DE69203767D1 (de) Verfahren zur Herstellung von organischen Düngemitteln.
DE69116070D1 (de) Verfahren zur Behandlung von Fruchtsaft unter hohem Druck
DE69017642D1 (de) Vorrichtung zur Herstellung von Einkristallen nach dem Czochralski-Verfahren.
DE58906148D1 (de) Verfahren zur Herstellung von Aminen.
DE69022269D1 (de) Verfahren zur thermischen Behandlung von Silizium.
DE69405850D1 (de) Verfahren und Vorrichtung zur Herstellung von flüssigem Stickstoff mit hoher Reinheit
DE68917003D1 (de) Verfahren zur Herstellung von Halbleiterbauelementen, die gegen Musterverunreinigungen geschützt sind.
DE59102077D1 (de) Verfahren zum Glasieren von Ton- und Prozellanwaren.
AT369719B (de) Verfahren zur thermischen behandlung von staubfoermigem gut, insbesondere zum brennen von zement, in mehreren stufen
DE3851461D1 (de) Verfahren zur Herstellung von Schattenmasken.
DE3883518D1 (de) Verfahren zur Herstellung von Silicium-Metall hoher Reinheit und Vorrichtung dafür.
DE59005265D1 (de) Verfahren zur Herstellung von Aminen.
ATA121992A (de) Verfahren zum trocknen und/oder brennen von ziegelrohlingen
DE3789680D1 (de) Verfahren zur Herstellung von Halbleiterbauelementen.
DE3883407D1 (de) Verfahren zur Herstellung von Fruit-Chips.
ATE138654T1 (de) Verfahren zur herstellung von 1-carbamoyl- pyrazolen
DE68923312D1 (de) Verfahren zur Herstellung von Caprolactam mit hoher Reinheit.
DE3880956D1 (de) Verfahren und vorrichtung zum regeln des herstellens von glasfasern.
ATE13976T1 (de) Verfahren zur gewinnung von bienenkittharz enthaltenden produkten und bienenkittharz enthaltende produkte.
DE59004399D1 (de) Verfahren zur Herstellung von Aminen.
DE59202144D1 (de) Verfahren und vorrichtung zum formstabilisieren von teigwaren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time